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Abstract
Regulated intramembrane proteolysis of the amyloid precursor protein (APP) by the protease activities a-, b- and c-
secretase controls the generation of the neurotoxic amyloid b peptide. APLP2, the amyloid precursor-like protein 2, is a
homolog of APP, which shows functional overlap with APP, but lacks an amyloid b domain. Compared to APP, less is known
about the proteolytic processing of APLP2, in particular in neurons, and the cleavage sites have not yet been determined.
APLP2 is cleaved by the b-secretase BACE1 and additionally by an a-secretase activity. The two metalloproteases ADAM10
and ADAM17 have been suggested as candidate APLP2 a-secretases in cell lines. Here, we used RNA interference and found
that ADAM10, but not ADAM17, is required for the constitutive a-secretase cleavage of APLP2 in HEK293 and SH-SY5Y cells.
Likewise, in primary murine neurons knock-down of ADAM10 suppressed APLP2 a-secretase cleavage. Using mass
spectrometry we determined the proteolytic cleavage sites in the APLP2 sequence. ADAM10 was found to cleave APLP2
after arginine 670, whereas BACE1 cleaves after leucine 659. Both cleavage sites are located in close proximity to the
membrane. c-secretase cleavage was found to occur at different peptide bonds between alanine 694 and valine 700, which
is close to the N-terminus of the predicted APLP2 transmembrane domain. Determination of the APLP2 cleavage sites
enables functional studies of the different APLP2 ectodomain fragments and the production of cleavage-site specific
antibodies for APLP2, which may be used for biomarker development.
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Introduction
Regulated intramembrane proteolysis (RIP) occurs for an
increasing number of membrane proteins, and is a molecular
mechanism controlling the communication between cells [1,2]. In
the RIP process a membrane protein typically undergoes two
consecutive proteolytic cleavages. The first one happens outside of
the membrane and results in shedding of the ectodomain. The
second cleavage, called intramembrane proteolysis, occurs within
the transmembrane domain and leads to the secretion of a small
peptide and the release of the intracellular domain into the cytosol.
The proteolytic cleavage fragments act as versatile signaling
molecules or are further degraded [3,4]. RIP also occurs for the
amyloid precursor protein (APP) family. This family comprises
APP itself as well as its two homologs amyloid precursor-like
proteins 1 and 2 (APLP1, APLP2) [5]. APP and APLP2 are
ubiquitously expressed, whereas expression of APLP1 is restricted
to the nervous system. The biological function of the APP protein
family members is not yet fully understood. The three proteins are
required for embryonic development, because in mice the triple
knock-out of APP, APLP1 and APLP2 results in perinatal lethality,
cranial abnormalities and cortical dysplasias [6]. In contrast, mice
singly deficient in either APP, APLP1 or APLP2 alone as well as
the double knock-out of APP and APLP1 do not show a phenotype
or only a mild one [7,8,9,10], suggesting functional overlap
between the three family members. However, the double knock-
out of APLP2 with either APP or APLP1 results in postnatal
lethality [9,10]. Together, these studies demonstrate that APLP2 is
particularly required for normal embryonic development and can
compensate for the lack of APP or APLP1.
APP, APLP1 and APLP2 undergo shedding in their ectodomain
by proteases referred to as a- and b-secretases, followed by c-
secretase-mediated intramembrane proteolysis. The cleavage of
APP is intensively studied, as APP is the precursor for the amyloid
b peptide (Ab), which has a key role in Alzheimer’s disease (AD)
pathogenesis [11]. APP cleavage by b- and c-secretase generates
Ab, whereas cleavage by a-secretase prevents Ab generation
[12,13]. APLP1 and APLP2 do not contain an Ab domain and are
not assumed to contribute to AD.
Despite the crucial function of APLP2 as described above, much
less is known about the proteolytic cleavage of APLP2 compared
to APP. Similar to APP, the type I membrane protein APLP2
undergoes shedding by the b-secretase BACE1 (b-site APP
cleaving enzyme), which results in secretion of the N-terminal
APLP2 ectodomain and in generation of the corresponding
membrane-bound C-terminal fragments (CTFs) [14,15,16,
17,18]. APLP2 also undergoes shedding by a-secretase. Although
the name a-secretase was initially coined for the metalloprotease
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cleaving APP, a-secretase is now used more widely to indicate the
shedding of membrane proteins by a metalloprotease, typically of
the ADAM (A disintegrin and metalloprotease) family. As
expected for a cleavage by ADAM proteases, a-secretase cleavage
of APLP2 occurs constitutively and is reduced by the metallopro-
tease inhibitors TAPI-2 or GM6001 [14,15]. Moreover, APLP2 a-
secretase cleavage can be stimulated above its constitutive level by
the phorbol ester PMA [14]. The constitutive a-secretase cleavage
of APLP2 seems to be mediated by ADAM10 and ADAM17 (also
known as TACE - TNFa converting enzyme). Overexpression of
ADAM10 or ADAM17 in kidney cells and of ADAM10 in mouse
brain increases APLP2 shedding [14,19]. Conversely, the
metalloprotease inhibitor GI254023X reduces APLP2 shedding
down to 30%. Because this inhibitor is 100-fold more potent in
inhibiting recombinant ADAM10 than ADAM17, it was conclud-
ed that ADAM10 may be the primary a-secretase for APLP2 [14].
However, overexpression of a dominant-negative ADAM10
reduced APLP2 shedding only by 40% [14], raising the possibility
that ADAM17 is also involved in constitutive APLP2 shedding. In
fact, ADAM17, but not ADAM10, is required for APLP2
shedding in SH-SY5Y cells stimulated with insulin-like growth
factor-1 [20]. So far, the constitutive APLP2 shedding has not yet
been analyzed in primary neurons. Taken together, it remains
unclear whether only ADAM10 or also ADAM17 contributes to
the constitutive a-secretase cleavage of APLP2. A similar situation
was observed for APP, where ADAM10 and 17 as well as other
metalloproteases were discussed as the constitutive APP a-
secretases. Recently, we demonstrated that only ADAM10, but
not ADAM17, mediates the constitutive APP a-secretase cleavage
in different cell lines and in primary murine neurons [21].
Ectodomain shedding can produce soluble protein fragments with
biological activity, for example growth factors and cytokines [3,4].
Likewise, it is clear that the soluble APP ectodomain can be
biologically active. For example, the APP ectodomain released
through b-secretase cleavage (APPsb) binds and activates the death
receptor DR6, acting in a proapoptotic manner [22]. Additionally, it
is able to induce expression of transthyretin and Klotho [23]. In
contrast, the a-secretase-cleaved APP (APPsa) has neurotrophic and
neuroprotective properties [24,25,26] and is able to rescue the mild
phenotype of APP single knock-out mice [27]. Together, this
demonstrates that APPsa and APPsb have different biological
functions, although APPsa is only 16 amino acids longer than APPsb
[28]. Thus, it is essential to know the cleavage sites and the identity of
the contributing protease activities in order to study the physiological
functions of the APP cleavage products in depth. Compared to APP
much less is known about the proteolytic cleavage of APLP2 and its
functional consequence. The a-, b- and c-cleavage sites for APLP2
have not yet been determined [5]. Thus, it remains unknown whether
– similar to APP – a- and b-secretase produce APLP2 ectodomains of
different length and diverse functions.
Here we demonstrate that the constitutive a-secretase cleavage
of APLP2 in HEK293 and in neuroblastoma SH-SY5Y cells is
mediated by ADAM10, but not by ADAM17. Furthermore,
knock-down of ADAM10 completely abolished a-secretase
cleavage of APLP2 in primary murine neurons, demonstrating
that ADAM10 is the constitutive a-secretase for APLP2.
Moreover, we determined the cleavage sites of a-, b- and c-
secretase in the APLP2 sequence.
Results
APLP2 is processed by an a-secretase
Human neuroblastoma SH-SY5Y cells shed three different
soluble species (sAPLP2) of the endogenous APLP2 (Fig. 1A). As
reported previously [14,29,30], the broad band between 120 and
160 kDa (***) corresponds to sAPLP2 carrying chondroitin sulfate
glycosamino glycans (CS-GAG) at serine 614 of the 751 amino
acids long APLP2 isoform 2. Due to heterogeneity in the amount
of glycosylation, this form is detected as a broad band. The two
sharp bands at apparent molecular weights of 115 and 100 kDa
are assumed to be non-CS-GAG modified, mature sAPLP2 (**)
and a truncated form of non-CS-GAG modified, mature sAPLP2
(***), respectively. sAPLP2 species are complex glycosylated as
shown by their resistance to endoglycosidase H treatment. In the
cell lysate full-length APLP2 was detected as two immature bands
(marked ** and ***, Fig. 1A), which were endoglycosidase H
sensitive (Fig. 1B), and as the CS-GAG modified APLP2 (*;
Fig. 1A). All protein bands are specific for APLP2, because they
were absent upon RNAi-mediated knock-down of APLP2
(Fig. 1A). As a positive control for the deglycosylation assay,
deglycosylation was performed for the b-secretase BACE1. In
agreement with previous studies [31,32,33], the mature form (#)
was sensitive to N-glycosidase F, but not to endoglycosidase H,
whereas the immature form (##) was sensitive to both
glycosidases.
Next, we determined to which extent APLP2 shedding occurs
by a- and b-secretase in SH-SY5Y cells. Treatment with the broad
spectrum metalloprotease inhibitor TAPI-1, which also inhibits
ADAM proteases, reduced APLP2 shedding down to less than
20% in SH-SY5Y cells (Fig. 1C and quantification in Fig. 1D),
demonstrating that APLP2 shedding is mediated to a large extent
by a-secretase, in agreement with previous publications [14,15].
As a control, TAPI-1 also inhibited the shedding of APP (Fig. 1C).
The inhibitor C3, which is specific for the b-secretase BACE1
[34], did not lead to a significant reduction of total APLP2
shedding, revealing that b-secretase cleavage only contributes to a
minor extent to total APLP2 shedding. This was further confirmed
by the combined use of TAPI-1 and C3, which did not decrease
total APLP2 shedding further than the use of TAPI-1 alone
(Fig. 1C and D). The remaining small amount of APLP2 shedding
may result from an as yet unknown protease different from a- and
b-secretase. Alternatively, TAPI-1 may not be able to completely
block a-secretase cleavage of APLP2.
Constitutive a-secretase cleavage of APLP2 is mediated
by ADAM10 in HEK293 and SH-SY5Y cells
To determine whether constitutive a-secretase cleavage of
APLP2 is mediated by ADAM10 or ADAM17 or both, a transient
knock-down of both proteases was performed in SH-SY5Y cells
(Fig. 2A and quantification in Fig. 2B). The siRNA pools efficiently
reduced the protein levels of ADAM10 and ADAM17 (Fig. 2A).
Knock-down of ADAM17 did not affect APLP2 shedding, ruling
out the possibility that ADAM17 is the constitutive APLP2 a-
secretase. In contrast knock-down of ADAM10 inhibited APLP2
shedding by ,70%, which is similar to the reduction of APLP2
shedding obtained with the metalloprotease inhibitor TAPI-1
(Fig. 1D). The inhibitor was slightly more potent than the siRNA
in reducing APLP2 shedding, most likely due to the fact that the
siRNA-mediated knock-down is not able to completely suppress
ADAM10 protein levels. In a previous study we found 10–15% of
ADAM10 protein remaining in the siRNA treated cells [21]. The
shedding of all three sAPLP2 species was reduced to a similar
extent (Fig. 2A and quantification in 2B). To rule out the
possibility that the results obtained are cell line-specific, the same
experiment was carried out in human embryonic kidney 293 cells
(HEK293). Very similar to the SH-SY5Y cells, ADAM10, but not
ADAM17, was essential for a-secretase cleavage of APLP2 (Fig. 2C
and quantification in 2D).
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To further validate this finding, SH-SY5Y cells with a stable
knock-down of ADAM10 were used [21]. Similar to the transient
ADAM10 knock-down, both shRNA sequences, which efficiently
reduce ADAM10 protein levels [21], inhibited APLP2 shedding by
60–80% (Fig. 2E and quantification in 2F).
The a-secretase ADAM10 generates the soluble APLP2
ectodomain and additionally the membrane-bound C-terminal
fragments (CTFs) of APLP2, which should be reduced in
ADAM10 knock-down cells. As the CTFs are rapidly further
cleaved by c-secretase, we stabilized them with the c-secretase
inhibitor DAPT [35] in wild-type SH-SY5Y cells or cells with a
knock-down of ADAM10. DAPT treatment led to an accumula-
tion of the CTFs (Fig. 2G), which were not visible in the absence of
DAPT or upon knock-down of APLP2 (not shown). Three CTF
bands were detected. Two have an apparent molecular weight of
approximately 10 kDa (-, --), in agreement with previous
publications [14,17,18]. One additional study detected six
different CTFs, which may be specific for the overexpression of
a C-terminally tagged APLP2 construct used in that study [15].
The third band that we observed is at approx. 8 kDa (#, Fig. 2G).
The lower of the two bands at 10 kDa was absent in the ADAM10
knock-down cells, demonstrating that it is the ADAM10-generated
CTF. The upper band was absent upon treatment with the b-
secretase inhibitor C3 (Fig. 2G), showing that it is produced by the
b-secretase BACE1, which is in agreement with previous studies
analyzing the CTFs generated upon BACE1 overexpression or
knock-out [17,18]. The intensity of the CTFs may suggest a
relatively large contribution of BACE1 to total APLP2 cleavage,
whereas the shedding analysis (Fig. 1B) revealed only a minor
contribution of BACE1 to APLP2 shedding. This difference is
likely due to the fact, that a c-secretase inhibitor was used for
detecting the endogenous APLP2 CTFs, such that also the b-
secretase generated CTF accumulates, even if it is only generated
at much lower levels compared to the a-secretase generated CTF.
Levels of the 8 kDa CTF were not significantly affected by
ADAM10 knock-down or C3 treatment (t-test significance value
p.0.1; n= 6), suggesting that it is generated by an additional
protease unrelated to ADAM10 and BACE1. Because this
fragment was not described in previous studies, it may only be
seen upon c-secretase inhibition.
From the above experiments we conclude that ADAM10, but
not ADAM17, is required for the constitutive APLP2 a-secretase
cleavage in SH-SY5Y and HEK293 cells.
APLP2 shedding in primary neurons
Next, we analyzed whether ADAM10 is also required for
APLP2 a-secretase shedding in primary neurons. Embryonic
neurons were prepared at E16. First, we used pharmacological
inhibitors of a- and b-secretase to evaluate their contribution to
the total amount of APLP2 shedding in neurons. The specific b-
secretase inhibitor C3 [34] reduced endogenous sAPLP2 levels by
about 50%, whereas the metalloprotease inhibitor TAPI-1
Figure 1. Analysis of APLP2 shedding using protease inhibi-
tors. (A) Human neuroblastoma SH-SY5Y cells were transiently
transfected with an siRNA pool against APLP2 or with a control pool.
Endogenous APLP2 was detected with the N-terminally binding 2D11
antibody. Bands were absent upon knock-down of APLP2 (APLP2KD),
demonstrating the specificity of the antibody. Soluble APLP2 (sAPLP2)
was detected in the conditioned medium, cellular full-length APLP2
(cell. APLP2), cellular full-length APP (cell. APP) and calnexin as a loading
control in the cell lysate. Three forms of APLP2 were detected: CS-GAG
modified (*) and two non-CS-GAG modified species (** and ***) with
molecular weights of around 115 and 100 kDa respectively. (B)
Deglycosylation of APLP2 in conditioned medium and cell lysate of
SH-SY5Y cells using endoglycosidase H (H) and N-glycosidase F (F).
Deglycosylated forms of APLP2 are indicated (-- and ---). As a control,
deglycosylation was performed for BACE1 in the cell lysate of BACE1
overexpressing HEK293 cells. Mature (#), immature (##) and
deglycosylated (###) BACE1 is detectable. (C) Representative blots
of treatment of SH-SY5Y cells with C3 (1 mM), TAPI-1 (50 mM) or
C3+TAPI-1. Upon C3 treatment no significant reduction of sAPLP2 levels
was observed. Upon TAPI-1 and C3+TAPI-1 treatment sAPLP2 levels
were strongly reduced while no changes in APLP2 levels in the cell
lysate were observed. As a control, soluble APP (sAPP) levels were
clearly reduced upon TAPI-1 and C3+TAPI-1 treatment. (D) Quantifica-
tion of experiments in C (mean +/2 SEM). C3 treatment did not lead to
a significant reduction in sAPLP2 levels while TAPI-1 as well as C3+TAPI-
1 treatment led to a significant reduction in sAPLP2 levels (p,0.001 for
all three species, n = 6).
doi:10.1371/journal.pone.0021337.g001
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reduced it by about 35% (Fig. 3A and quantification in 3B). Thus,
compared to HEK293 cells, APLP2 shedding in neurons is
mediated to a larger extent by the b-secretase BACE1. This is
similar to APP and is in agreement with the finding that BACE1 is
expressed at higher levels in neurons than in cell lines [21,36,37].
Due to alternative splicing of APLP2, which destroys the CS-GAG
attachment site, neurons have less of the CS-GAG-modified
APLP2 compared to HEK293 or SH-SY5Y cells (Fig. 2A, B)
[38,39]. Next, ADAM10 was efficiently knocked-down in the
primary neurons (Fig. 3C) using lentiviruses expressing two distinct
and validated shRNAs against ADAM10 [21,40]. sAPLP2 levels
were reduced by about 30% (Fig. 3C and quantification in 3D).
This is similar to the metalloprotease inhibitor TAPI-1 (Fig. 3A)
and demonstrates that the constitutive a-secretase cleavage of
APLP2 in neurons is mediated by ADAM10.
APLP2 a-secretase cleavage occurs at the Arg670-Val671
peptide bond
The cleavage sites of APLP2 by either ADAM10 or BACE1
have not yet been identified. To determine them, mass
spectrometry was used. The intensive glycosylation of APLP2
would lead to a broadening of the peaks in the mass spectrometric
analysis, making identification of specific cleavage sites difficult.
Thus, similar to a previous study analyzing APP cleavage [21], two
short peptide tags were included into the APLP2 ectodomain C-
terminally of the glycosylation sites at a distance of 39 amino acids
from the suggested transmembrane domain (Fig. 4A). One of the
two peptide sequences encodes a tobacco etch virus (TEV)
protease cleavage site, the other one encodes a FLAG tag. This
mutant APLP2-TEV-FLAG construct (APLP2TF) was transiently
expressed in HEK293 cells. The metalloprotease inhibitor TAPI-1
strongly inhibited shedding of APLP2TF (Fig. 4B), demonstrating
that APLP2TF was processed like the wild-type, endogenous
APLP2 (Fig. 1B).
For this study the longest APLP2 isoform (763 amino acids) was
used, which lacks the CS-GAG modification. The secreted form of
APLP2-TF was immunoprecipitated from the conditioned medi-
um with an anti-FLAG antibody and then digested in vitro with
TEV protease. This leads to the removal of the glycosylated part of
the APLP2 ectodomain, resulting in ,3 kDa peptides having the
FLAG tag at their new N-terminus and C-terminally ending at the
peptide bond, where APLP2 is shed by the secretases (Fig. 4A).
Mass spectrometric measurements yielded two peptide peaks at
2917.34 Da and at 3073.37 Da, which correspond to the peptides
having glutamate 669 and arginine 670 respectively as their C-
terminal amino acid (Fig. 4C and D). Overexpression of ADAM10
strongly increased APLP2TF shedding (Fig. 4E). The same two
Figure 2. Transient and stable knock-down of ADAM10
suppresses APLP2 shedding. (A) SH-SY5Y cells were transfected
with siRNA pools against the proteases ADAM10 (A10KD) or ADAM17
(A17KD) or with control siRNA (Con). Both proteases were detected in
membrane preparations. The mature active form is indicated with ##,
the immature form with #. Actin and full-length APLP2 levels (cell.
APLP2) were detected in the cell lysate. Conditioned media were
analyzed for total secreted APLP2 (sAPLP2). All three species of sAPLP2
(* CS-GAG modified, ** 115 kDa, *** 100 kDa) were strongly decreased
upon knock-down of ADAM10, but not of ADAM17. (B) Quantification
of experiments in A (mean +/2 SEM). ADAM10 knock-down signifi-
cantly reduced sAPLP2 (p,0.001 for all three species, n = 6), while
ADAM17 knock-down did not lead to any significant changes in sAPLP2
levels. (C) Knock-down of ADAM10 and ADAM17 in HEK293 cells,
carried out as in A. (D) Quantification of experiments in C (mean +/2
SEM). ADAM10 knock-down significantly reduced sAPLP2 (p,0.001 for
CS-GAG modified and 100 kDa APLP2, p = 0.001 for 115 kDa APLP2,
n = 6). (E) SH-SY5Y cells with stable shRNA-mediated knock-down of
ADAM10 were used. shRNAs sh7 and sh9 are targeting two different
regions of ADAM10. As control, a stable SH-SY5Y cell line expressing a
non-targeting shRNA was used (Con). sAPLP2 levels were clearly
reduced upon ADAM10 knock-down. (F) Quantification of experiments
in E (mean +/2 SEM). Both shRNAs significantly reduced sAPLP2
(p,0.001 for all three species, n = 6). (G) SH-SY5Y cells were transiently
transfected with a siRNA pool against ADAM10 (A10KD) or control
siRNA (Con). Cells were treated with DAPT (1 mM). Additionally C3
(1 mM) or DMSO (as a solvent control) was applied. sAPLP2 levels were
clearly reduced upon ADAM10 knock-down while cellular APLP2 levels
(cell. APLP2) remained unchanged. Two forms of APLP2 C-terminal
fragments (CTFs) were detected at around 10 kDa in the cell lysate (-,--).
ADAM10 knock-down led to the elimination of the lower molecular
weight APLP2 CTF (--) while C3-treatment abolished the higher
molecular weight species (-).
doi:10.1371/journal.pone.0021337.g002
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peptide peaks were observed under control conditions, but with a
much higher intensity (TIC, total ion count, Fig. 4C), indicating
that both peptides directly derive from ADAM10-mediated
cleavage. Given that ADAM10 preferentially cleaves after arginine
or lysine [41], we assume that the primary ADAM10 cleavage site
in APLP2 is after arginine 670 and then followed by an as yet
unidentified carboxypeptidase cleavage, similar to what is known
for APP [21,42]. This is in agreement with our observation that
the ratio of the two peptides depends on the duration of the
incubation of the supernatant on the cells, with longer incubations
leading to a shift towards the shorter product (data not shown).
Overexpression of BACE1 increased APLP2TF shedding
(Fig. 4E) and suppressed the ADAM10-generated peptide peaks
and yielded a shorter peptide with 1740.72 Da (Fig. 4C),
corresponding to leucine 659 as the C-terminal amino acid
(Fig. 4D). The leucine is in good agreement with the substrate
specificity of BACE1 known from in vitro experiments [43] and is
also found in other BACE1 substrates, such as the Swedish variant
APP and P-selectin glycoprotein ligand-1 [44] (Fig. 4G). The
BACE1-generated peptide was not detected under control
conditions. As the BACE1 cleavage makes up a very small
proportion of total APLP2 shedding (see C3-inhibitor treatment in
Fig. 1B), it is likely that this peptide was below the detection limit
in our analysis.
Heterogeneous c-secretase cleavage occurs between
alanine 694 and valine 700
After ectodomain shedding APLP2 undergoes intramembrane
proteolysis by c-secretase [15]. While the so-called e-cleavage site
at the C-terminal end of APLP2 has been mapped to occur after
leucine 712 [45], the c-cleavage sites remain unknown. For
identification of the c-secretase cleavage sites the APLP2 CTF was
stably expressed in HEK293 cells. The CTF construct was
composed of the N-terminal HA-tag, a short linker region,
followed by the APLP2-CTF starting on proline 683. The
construct further harbored a C-terminal FLAG-tag fused to the
end of the CTF (Fig. 5A, HA-APLP2CTF-FLAG). As a control,
the c-secretase inhibitor Merck A [46] blocked c-secretase
cleavage of the CTF, as evidenced by increased CTF levels
(Fig. 5B).
Figure 3. APLP2 processing in primary cortical neurons. (A) E16 primary cortical neurons were treated with C3 (1 mM), TAPI-1 (50 mM) or
DMSO as a solvent control. sAPLP2 (* CS-GAG-modified, ** 115 kDa, *** 100 kDa) was detected in the conditioned medium of these cells. Full-length
cellular APLP2 (cell. APLP2) and actin were detected in the cell lysate. A clear reduction of sAPLP2 levels was observable upon C3 as well as TAPI-1
treatment. (B) Quantification of experiments in A (mean +/2 SEM). C3 and TAPI-1 significantly reduced sAPLP2 (C3: p,0.001 for both detected
species, TAPI-1: p,0.001 for CS-GAG modified APLP2, p = 0.004 for mature APLP2; n = 6). (C) E16 primary cortical neurons with lentiviral knock-down
of ADAM10 were analyzed. shRNAs (sh-I and sh-II) targeting different regions of ADAM10 and a non-targeting shRNA control (Con) were used. A clear
reduction of ADAM10 (# immature, ## mature) levels was observed in the cell lysate and of sAPLP2 in the conditioned medium. (D) Quantification
of experiments in C (mean +/2 SEM). Both shRNAs significantly reduced sAPLP2 (p,0.01 for both detected species for both shRNAs, n = 6).
doi:10.1371/journal.pone.0021337.g003
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Figure 4. Mass spectrometry-based determination of APLP2 a- and b-shedding sites. (A) Scheme of experimental procedure. A TEV-
protease cleavage site followed by a FLAG-tag was introduced into APLP2 isoform 763 starting after amino acid M653 (APLP2TF). The TEV-FLAG site is
positioned 39 amino acids N-terminally of the assumed start of the transmembrane domain (TMD). Shedding yields sAPLP2TF, which was
immunoprecipitated and digested with TEV-protease, leading to a small peptide harboring the N-terminal FLAG-tag as well as the C-terminal
cleavage site resulting from the shedding. This peptide was analyzed in a mass spectrometer. (B) HEK293 cells were transiently transfected with the
APLP2TF construct and either treated with TAPI-1 (50 mM) or DMSO as a solvent control. Upon TAPI-1 treatment secreted sAPLP2TF levels were clearly
decreased in the conditioned medium of the cells. An accumulation of APLP2TF levels was observed upon TAPI-1 treatment in the cell lysate. Actin
Proteolytic Processing of APLP2
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The secreted peptides resulting from c-secretase cleavage were
immunoprecipitated from the supernatant and analyzed by
MALDI-TOF mass spectrometry. Seven peaks were identified in
the range of 3000 to 3700 Da with the main peak showing a mass
of 3404.47 Da (Fig. 5C). This implies that the main c-secretase
cleavage site is the peptide bond between leucine 698 and leucine
699 (Fig. 5D). Multiple c-secretase cleavage sites are typically
detected for c-secretase substrates, including APP [47].
As a control, we verified that the identified peptides were
generated in a c-secretase-dependent manner. In fact, the c-
secretase inhibitor Merck A strongly reduced the seven mass peaks
(Fig. 5C). Because mass spectrometry is only semi-quantitative, we
further verified this finding by using a truly quantitative mass
spectrometry technique, called SILAC (stable isotope labeling with
amino acids in cell culture) [48]. In this approach cells from two
different experimental conditions, such as with and without Merck
A, are grown in the presence of isotopically light (with Merck A) or
heavy (without Merck A) amino acids arginine and lysine. The
combined supernatants are then analyzed by mass spectrometry.
To demonstrate the method, the stably HA-APLP2CTF-FLAG
expressing HEK293 cells were first grown without Merck A
(control) in either light or heavy medium. Labeling efficiency was
above 90% as determined by mass spectrometry based analysis of
the cell lysate of the heavy labeled cells (Fig. 5E). Upon growth in
the ‘heavy’ medium, the cells incorporated the heavy labeled
amino acids into their proteins thereby increasing the molecular
weight of the APLP2 CTF-derived peptides by +10 Da due to the
single arginine found in every of the seven peptides (Fig. 5F, upper
panel). Addition of Merck A to the ‘light’ labeled cells strongly
reduced the ‘light’ peaks relative to the ‘heavy’ peaks from the
solvent control (DMSO)-treated cells (Fig. 5F, lower panel),
demonstrating that all seven peaks result from c-secretase
cleavage.
Discussion
Ectodomain shedding regulates the activity of membrane
proteins and is frequently the regulatory step for subsequent
intramembrane proteolysis [2,49]. Shedding is often mediated by
ADAM-proteases, in particular by ADAM10 and ADAM17. Both
proteases have overlapping specificities in vitro [41] and
overexpression of either one can increase the shedding of some
substrates, whereas under physiological conditions frequently only
of the two proteases cleaves a given substrate. Here, we
demonstrate that this is also the case for APLP2. We found that
the constitutive a-secretase cleavage of the APP homolog APLP2 is
mediated by ADAM10, but not by ADAM17. Also in neurons,
where we investigated APLP2 shedding for the first time,
ADAM10 was essential for constitutive APLP2 a-secretase
cleavage. A similar situation was previously found for APP.
Although ADAM10 and ADAM17 and even ADAM9 can cleave
APP and stimulate its shedding under overexpression conditions
[50,51,52], only ADAM10, but not ADAM9 or ADAM17, was
recently shown to mediate the constitutive APP a-secretase
shedding [21].
Our study reveals further similarities, but also differences
between the constitutive shedding of the two homologs APP and
APLP2. First, in cell lines, both proteins are predominantly
cleaved by a-secretase and only to a low extent by b-secretase,
whereas in primary neurons, which express higher levels of the b-
secretase BACE1, APP and APLP2 are cleaved to at least 50% by
b-secretase. Second, for both proteins the initial a-secretase
cleavage appears to be followed by a carboxypeptidase cleavage
removing the C-terminal, positively charged amino acid (Lys in
APP, Arg in APLP2). While the functional relevance of this C-
terminal truncation is not yet clear, it is interesting to note that the
maturation of several prohormones also requires the removal of a
C-terminal Lys or Arg by a carboxypeptidase [53]. Third, the a-
and b-cleavage sites occur at similar peptide bonds, which are in
agreement with the specificities of BACE1 and ADAM10 in vitro
[41,43]. Fourth, APP and APLP2 are cleaved at slightly different
distances from the membrane. For APP, the a-cleavage occurs at a
distance of 12 amino acids from the membrane. The b-cleavage is
a further 16 amino acids away. For APLP2 the a-cleavage is at a
distance of 22 amino acids from the membrane and the b-cleavage
is a further 11 amino acids away (Fig. 4G). In contrast to APP,
where a Lys is assumed to be the membrane-anchor and
determines the beginning of the transmembrane domain, the
boundaries of the transmembrane domain of APLP2 are less clear.
The N-terminal boundary is assumed to start at serine 693
(Fig. 4G), but is preceded by several non-charged amino acids,
which may also be part of the transmembrane domain. If that
were the case, the distance of the a- and b-secretase cleavage sites
in APLP2 would be even closer to the transmembrane domain and
thus, even more similar to APP (Figs. 4G and 5G). The exact
determination of the length of the APLP2 transmembrane domain
would require biochemical approaches, as previously carried out
for APP [54]. Although for APLP2 and APP the b-cleavage site is
further away from the membrane than the a-secretase cleavage
site, this is not the case for all membrane proteins undergoing
shedding by an a- and a b-secretase. For example, for the cell
adhesion protein P-selectin glycoprotein ligand-1, the cleavage site
by b-secretase is closer to the membrane than the cleavage site by
a-secretase [44].
Our finding that the constitutive a-secretase cleavage of APLP2
is mediated by ADAM10 is in agreement with previous reports
showing that APLP2 shedding is reduced by a dominant-negative
ADAM10 as well as by the metalloprotease inhibitor GI254023X
[14,19], which is more potent on ADAM10 than on ADAM17
[55]. However, another study reported that the knock-down of
ADAM17, but not of ADAM10, reduced APLP2 shedding [20]. In
that study, APLP2 shedding was not analyzed under constitutive
conditions, but after stimulation with IGF-1. This demonstrates
was analyzed in the cell lysate as a loading control. (C) Peptides produced according to the scheme in A were obtained from HEK293 cells transiently
overexpressing APLP2TF and either luciferase as a control, ADAM10 or BACE1. Mass spectrometric analysis of the peptides revealed two peaks for
control and ADAM10 overexpression (*,**) while upon BACE1 overexpression only one peak with a lower m/z ratio was observed. Total Ion Counts
(TIC) and centroid peak masses of the first isotopic peak are given for each isotopic peak cluster. All peaks are revealed from singly-charged peptides.
(D) Determined (Det.) masses of the peaks in C (*,**,***) were compared to calculated (calc.) masses. For each mass, a corresponding peptide could
be computed with less than 0.5 Da error. (E) Western Blot analysis of the samples used in C. sAPLP2TF was detected in the conditioned media, full-
length APLP2 (APLP2TF), ADAM10 (A10, # immature and ## mature), BACE1 and calnexin as a loading control were detected in the cell lysates. A
clear increase in sAPLP2TF levels was observed upon ADAM10 and BACE1 overexpression. sAPLP2TF has a slightly reduced apparent molecular
weight upon BACE1 overexpression if compared to control (Con). (F) Summary of known ADAM10 cleavage sites in different substrates aligned with
the newly detected ADAM10 cleavage site for APLP2 [41]. (G) Schematic comparison of the ectodomain shedding sites of APP and APLP2. The APP a-
cleavage occurs 12 amino acids N-terminally of the transmembrane domain (TMD), for APLP2 it occurs 22 amino acids N-terminally of the TMD. For
both proteins b-cleavage occurs N-terminally of an aspartate.
doi:10.1371/journal.pone.0021337.g004
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Figure 5. Mass spectrometry-based determination of APLP2 c-cleavage site. (A) Scheme of experimental procedure: the HA-APLP2CTF-
FLAG construct was stably expressed in HEK293 cells. The construct consists of an N-terminal HA-tag (HA), a linker region consisting of five glycines
(5G), the APLP2CTF sequence (APLP2) and an C-terminal FLAG-tag (FLAG). Upon c-secretase cleavage, peptides harboring the c-secretase cleavage
site at their C-terminus were liberated. Peptides were immunoprecipitated using HA-affinity agarose and subsequently analyzed in a MALDI-TOF mass
spectrometer. (B) Western Blot to confirm the c-secretase sensitivity of the construct. Cells stably expressing HA-APLP2CTF-FLAG were treated with
(M) or without (C, control) the c-secretase inhibitor Merck A. In the presence of Merck A the CTFs accumulated in the lysate. The same was observed
for cells grown in ‘light’ (L) or ‘heavy’ (H) medium. CTFs were detected with anti-FLAG antibody. Calnexin levels were analyzed as a loading control.
(C+D) Mass spectrometry-based identification of the c-secretase cleavage sites. Under control conditions, seven peaks were detected with a maximal
total ion count of 497. Upon Merck A treatment, the intensity (ion count) for the peaks was reduced significantly. Peaks are labeled with identifiers
#1–#7 linking them to the respective peptides sequences in the table (D). All peptides were detected with a mass error of less than 0.3 Da. (E)
Determination of the labeling efficiency for the SILAC experiment. To determine the labeling efficiency, proteins from the cell lysates of the ‘heavy’
labeled cells from (F) were separated on an SDS-PAGE gel. One band was cut out and tryptic in gel digestion was performed. Peptides resulting from
this digestion were analyzed in an LTQ Orbitrap Velos mass spectrometer. Proteins were identified by database search, and the labeling efficiency
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that the regulated APLP2 shedding – i.e. the increase above the
constitutive shedding level – can be mediated by proteases other
than the constitutively cleaving ADAM10. This is similar to APP,
where the constitutive a-secretase cleavage is mediated by
ADAM10, whereas the regulated a-secretase cleavage can be
mediated by ADAM17, at least upon stimulation with the phorbol
ester phorbol-12-myristate-13-acetate (PMA). Interestingly, the
IGF-1-stimulated shedding, which requires ADAM17 for APLP2,
requires ADAM10 for the APP cleavage [20]. This shows that a-
secretase shedding of APP and APLP2 can be regulated in a
different manner, despite the many similarities described above for
the constitutive a-secretase cleavage. It will be interesting to see
whether these differences also occur for other stimuli known to
activate APP and APLP2 shedding.
In contrast to a- and b-secretase, we found that c-secretase has
multiple cleavage sites in the transmembrane domain of APLP2.
This is also observed for other c-secretase substrates, such as APP
and Notch [47]. However, in contrast to APP the cleavage sites are
not located in the middle of the predicted transmembrane domain,
but are close to the N-terminal membrane boundary of APLP2
[15,56]. In APP the main c-cleavage site after amino acid 40 of the
Ab sequence is 12 amino acids away from both ends of the
transmembrane domain. In contrast, the main cleavage site in
APLP2 is only around six residues away from the N-terminal
membrane boundary. A similar situation is found for the c-
secretase substrate Notch-1, where the S4 cleavage site is also only
seven amino acids away from the N-terminal membrane boundary
[57]. Nevertheless, it may well be possible that the transmembrane
domain of APLP2 is in fact around five amino acids longer than
predicted at the N-terminal side, as discussed above for the a- and
b-secretase cleavage (Fig. 5G). In this case, the main c-cleavage
site in APLP2 would be 11 residues away from the N-terminal end
of the transmembrane domain and thus – similar to APP – roughly
be located in the middle of the transmembrane domain.
The determination of the a-, b- and c-secretase cleavage sites is
the basis for further developments in APLP2 research. It will allow
the generation of cleavage site-specific antibodies, which distin-
guish between the sAPLP2 forms generated by a- or b-secretase.
Such antibodies will not only be valuable tools for studying APLP2
cleavage by both proteases, but may also be useful for biomarker
studies in AD. In this disease, an increase in protein levels of
BACE1 and a reduction of a-secretase cleavage is observed
[reviewed in 28,58]. Potentially, the corresponding APLP2
cleavage fragments are changed in a similar way, which may be
an additional approach to discriminate between AD patients and
controls. This may be advantageous, as APLP2-derived peptides
should not aggregate and not form deposits due to the lack of the
Ab domain. Thus, their levels should not be influenced by
depositing peptides, similar to what was recently found for APLP1-
derived Ab-like peptides [59]. A second use of the cleavage sites of
APLP2 may be the dissection of the function(s) of APLP2.
Potentially, sAPLP2 generated by a- or b-secretase has different
functions, similar to what is known for APP. a-secretase-cleaved
APP acts in a neurotrophic and neuroprotective manner
[24,25,26], whereas b-secretase cleaved APP may be proapoptotic
[22].
Given that APPsa rescues the phenotype of APP single knock-
out mice [27], it will be interesting to see whether expression of the
a- or b-secretase-cleaved ectodomains of APP and APLP2
together are able to rescue the postnatal lethality in the APP/
APLP2 double knock-out mice [9,10]. Such studies will provide
further insights not only into the function of APLP2, but also of
APP and into the functional overlap or functional divergence
between both homologs.
Materials and Methods
Reagents
The following antibodies were used: FLAG M2 (Sigma),
HA.11 (Covance), ADAM10 (Calbiochem-422751), ADAM17
(Oncogene), APLP2 (Calbiochem-171617 and 171616) HRP-
coupled anti-rabbit and anti-mouse (DAKO), HRP-coupled anti-
rat (Santa Cruz), Calnexin (Stressgen), b-actin (Sigma), mono-
clonal antibody (mAb) 22C11 (anti-APP ectodomain) from
Konrad Beyreuther. The following reagents were used: a-
Cyano-4-hydroxy-cinnamic acid, anti-FLAG M2 and anti-HA
affinity gel from Sigma-Aldrich, metalloprotease inhibitor TAPI-
1, BACE inhibitor C3, c-secretase inhibitor X (referred to as
Merck A) [46] and Dodecyl maltoside (DDM) from Calbiochem;
siRNA pools siGenome against ADAM10 and 17, APLP2 and
corresponding controls from Dharmacon. Lipofectamine 2000,
RNAimax and TEV protease from Invitrogen; endoglycosidase
H and N-glycosidase F from Roche; Acetonitrile (ACN) and
trifluoracetic acid (TFA) from Fluka. SILAC media were from
Silantes.
Cloning
The APLP2-TEV-FLAG (APLP2TF) construct was cloned by
the introduction of a TEV-cleavage site (ENLYFQG) followed by
a FLAG-tag (DYKDDDDK) into the juxtamembrane region of
APLP2-763 subcloned into the pcDNA3.1 zeo (+) vector
(Invitrogen). The short peptide motifs were introduced between
the respective nucleotides corresponding to amino acids M653 and
V654 of the APLP2-763 sequence. Plasmids peak12-ADAM10,
peak12-BACE1 and peak12-luciferase have been described [44].
HA-APLP2CTF-FLAG construct was produced through subclon-
ing of the APLP2CTF into the backbone of a pcDNA 3.1 zeo (+)
vector containing the N-terminal HA-tag, the linker region
consisting of five glycines and the C-terminal FLAG-tag, which
was described before [60].
(Label. Eff.) was determined from the ‘heavy’ to ‘light’ ratios (Heavy/Light) of the quantifiable peptides. Further, coverage of the proteins in %
(Coverage), number of unique peptides identified (Peptides), molecular weight of respective protein (MW), SEQUEST score (Score) and number of
unique peptides used for quantification (H/L Count) are given. (F) Analysis of c-secretase-dependent CTF cleavage by quantitative mass
spectrometry. Upper panel: Cells without Merck A (Control) grown either in ‘light’ or in ‘heavy’ medium. Supernatants were combined, peptides
immunoprecipitated and analyzed in the MALDI-TOF mass spectrometer. Peaks resulting from the ‘light’ and the ‘heavy’ labeled peptides are clearly
separated (+10 Da as expected for one heavy labeled arginine). Intensities of corresponding ‘heavy’ and ‘light’ peak clusters are not identical, as the
‘heavy’ clusters are either shifted (+10 Da) or supershifted (+16 Da) due to additional incorporation of a ‘heavy’ proline resulting from arginine- to-
proline conversion. Lower panel: upon treatment of the ‘light’ labeled cells with Merck A and the ‘heavy’ labeled cells with DMSO as a solvent control,
the ratio between the intensity of the ‘light’ labeled peptides and the ‘heavy’ labeled peptides is significantly reduced if compared to the control
experiment. This demonstrates that the identified peptide peaks are generated by c-secretase. (G) Comparison of the position of the e- and c-
secretase cleavage sites of APP and APLP2 in an alignment of the juxtamembrane and the transmembrane region of these two proteins. The dark
boxes mark the predicted transmembrane domains (TMD), while the light box indicates amino acids which could potentially still be part of the
transmembrane domain, as they do not harbor charges.
doi:10.1371/journal.pone.0021337.g005
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Cell Culture, transfections, RNAi
HEK293-EBNA cells [21] were cultured in Dulbecco’s
modified Eagle medium (DMEM, Gibco) containing 10% fetal
calf serum (FCS/Gibco) as described [61,62]. SH-SY5Y cells
were cultured in F12/DMEM (Lonza) supplemented with 15%
FCS. SH-SY5Y cells with a lentivirus-induced stable knock-
down of ADAM10 (shRNAs 7 and 9) were previously described
[21]. Transient knockdown of ADAM10 and ADAM17 in
HEK293E and SHSY5Y cells was performed as described
[21]. In brief: Cells were transfected with either 10 nM
(HEK293E) or 2 nM (SHSY5Y) of siGenome pool siRNA
targeting ADAM10 or ADAM17 or the same amount of
control siRNA (C2-pool) using RNAimax. After two days,
transfection medium was replaced. After overnight incubation,
conditioned medium and cell lysate (in 150 mM NaCl, 50 mM
Tris pH 7.5, 1% Nonidet P-40) were collected. For detection of
ADAM 10 and ADAM17, cell membranes were prepared as
described previously [63]. Transient APLP2 knock-down was
performed using the siGenome pool siRNA in SH-SY5Y cells
(2 nM).
Deglycosylation analysis
For deglycosylation analysis of APLP2, supernatants and cell
lysates of SH-SY5Y cells were incubated either with or without 5
milliunits endoglycosidase H for 3 hours at 37uC or with or
without 2.5 units of N-glysosidase F for 17 hours at 37uC. As a
positive control, cell lysates from BACE1 overexpressing HEK293
cells were analyzed accordingly.
Generation of lentiviruses and transduction of primary
neurons
Primary neuronal cultures were obtained from the cerebral
cortex of embryonic day (E16) C57/BL6 mouse embryos,
incubated with 200 U of papain (Sigma Aldrich) (30 min at
34uC) and subsequently mechanically dissociated and transduced
using lentiviral shRNA knock-down constructs as described
[21,64]. Breeding, maintenance and all experimental procedures
on animals were approved and licensed by the Regierung von
Oberbayern, Munich and were performed in accordance with
German legislation and with the European Communities Council
Directive (86/609/EEC).
Inhibitor treatment
Inhibition of a-, b- and c-secretase was performed using TAPI-1
(50 mM), C3 (1 mM) and DAPT (1 mM) respectively. Merck A
(5 mM) was used as a further c-secretase inhibitor. For SH-SY5Y
or HEK293 cells, 1 or 2 days after plating, the supernatant was
exchanged with supernatant containing the respective inhibitors
and conditioned supernatants and cell lysates were collected
24 hours later. Inhibitor treatment of the primary neurons started
at 7DIV and was performed for 24 hours.
Determination of shedding sites
Determination of the shedding sites of APLP2 was performed as
described for APP [21]. From the supernatant of HEK293 cells
overexpressing pcDNA3.1/APLP2TF the shed ectodomain of
APLP2TF was purified using anti-FLAG M2 agarose. The
purified ectodomain was cleaved using TEV protease. The short
peptide produced was again purified via anti-FLAG M2 agarose
and subsequently analyzed in a Voyager-DE STR mass spec-
trometer (Applied Biosystems).
Determination of c-secretase cleavage sites
Peptides were purified from the supernatant from HEK293 cells
stably overexpressing HA-APLP2CTF-FLAG applying anti-HA
agarose and analyzed in a Voyager-DE STR mass spectrometer
(Applied Biosystems). For c-secretase inhibition supernatant from
cells was removed and cells were treated with Merck A (5 mM) for
24 h prior to supernatant collection and subsequent analysis.
SILAC experiment
HEK293 cells stably overexpressing HA-APLP2CTF-FLAG
were grown either in ‘light’ (12C6, 14N2 Lys; 12C6 14N4 Arg) or
in ‘heavy’ medium (13C6, 15N2 Lys; 13C6 15N4 Arg) for at least
six cell doublings before the actual experiment. For this, identical
numbers of cells were plated in ‘heavy’ or ‘light’ medium. After
overnight incubation the enriched medium was collected and
equal quantities from both ‘heavy’ and ‘light’ cell supernatant was
combined prior to immunoprecipitation with the anti-HA agarose.
Cell lysates were produced for subsequent determination of the
labeling efficiency.
Determination of labeling efficiency
For determination of the labeling efficiency, proteins from the
cell lysates of the cells grown in the ‘heavy’ medium were
separated on an SDS-Page gel. A band of the Coomassie stained
gel at an apparent mass of around 90 kDa was cut out and
tryptic in gel digestion of the proteins was performed [65].
Subsequently, peptides were analyzed by liquid chromatogra-
phy (EASY nLC II, Proxeon) coupled to tandem mass
spectrometry (LTQ Orbitrap Velos, Thermo) using a TOP10
method. Data analysis was performed using the Proteome
Discoverer 1.2 (Thermo) with the embedded SEQUEST
algorithm for protein identification. The International Protein
Index database for human (version 3.78) was used for the
database search with carbamidomethylation of cysteine as a
static and oxidation of methionine as a dynamic modification.
Quantification was performed using the ‘precursor ions
quantifier’ node of the Proteome Discoverer 1.2.
Labeling efficiency was further validated in a control
experiment. Equal amounts of supernatant from untreated
‘light’ and untreated ‘heavy’ labeled HA-APLP2CTF-FLAG
HEK293 cells were combined and subsequent immunoprecip-
itation was performed as described above. The area under the
isotopic peak cluster of every ‘light’ peptide was compared to the
area under the isotopic peak cluster of the corresponding ‘heavy’
peptide. For the ‘heavy’ peptide, the +10 Da shifted (one 13C6
15N4 Arg per peptide) and the +16 Da supershifted (one 13C6
15N4 Arg and one 13C5 15N1 Pro per peptide) istopic peak
clusters were combined, as arginine-to-proline conversion
played a significant role in our experiment [66]. Labeling
efficiency was also found to be above 90% when determined by
this method.
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